EAA173
Duratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETERSMM)
More Information
SWOG S1803
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MMM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
More Information
INCB 00928-105
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
More Information
MEDICI
MEDICI - t(11;14) and BCL2 expression in patients with multiple myeloma: Prevalence, stability across lines of therapy, and concordance across sample types
More Information
TNB383B.0001
A Multicenter, Phase 1, Open-label, Dose-Escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
More Information
M21-406
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma
More Information
